127 related articles for article (PubMed ID: 38095042)
1. Unveiling the role of MGMT and DAPK hypermethylation in response to anti-EGFR agents: Molecular insights for advancing HNSCC treatment.
Arantes LMRB; Silva-Oliveira RJ; de Carvalho AC; Melendez ME; Sorroche BP; de Jesus Teixeira R; Tostes K; Palmero EI; Reis RM; Carvalho AL
Head Neck; 2024 Mar; 46(3):461-472. PubMed ID: 38095042
[TBL] [Abstract][Full Text] [Related]
2. Comparison of promoter hypermethylation pattern in salivary rinses collected with and without an exfoliating brush from patients with HNSCC.
Sun W; Zaboli D; Liu Y; Arnaoutakis D; Khan T; Wang H; Koch W; Khan Z; Califano JA
PLoS One; 2012; 7(3):e33642. PubMed ID: 22438973
[TBL] [Abstract][Full Text] [Related]
3. Promoter methylation of MGMT, MLH1 and RASSF1A tumor suppressor genes in head and neck squamous cell carcinoma: pharmacological genome demethylation reduces proliferation of head and neck squamous carcinoma cells.
Koutsimpelas D; Pongsapich W; Heinrich U; Mann S; Mann WJ; Brieger J
Oncol Rep; 2012 Apr; 27(4):1135-41. PubMed ID: 22246327
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines.
De Pauw I; Lardon F; Van den Bossche J; Baysal H; Fransen E; Deschoolmeester V; Pauwels P; Peeters M; Vermorken JB; Wouters A
Mol Oncol; 2018 Jun; 12(6):830-854. PubMed ID: 29603584
[TBL] [Abstract][Full Text] [Related]
5. Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.
Nakamura Y; Togashi Y; Nakahara H; Tomida S; Banno E; Terashima M; Hayashi H; de Velasco MA; Sakai K; Fujita Y; Okegawa T; Nutahara K; Hamada S; Nishio K
Mol Cancer Ther; 2016 Aug; 15(8):1988-97. PubMed ID: 27207775
[TBL] [Abstract][Full Text] [Related]
6. Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment-induced reduction in EGFR, pEGFR, and pSrc.
Jedlinski A; Garvin S; Johansson AC; Edqvist PH; Ponten F; Roberg K
J Oral Pathol Med; 2017 Oct; 46(9):717-724. PubMed ID: 28036101
[TBL] [Abstract][Full Text] [Related]
7. Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
Quesnelle KM; Wheeler SE; Ratay MK; Grandis JR
Cancer Biol Ther; 2012 Aug; 13(10):935-45. PubMed ID: 22785204
[TBL] [Abstract][Full Text] [Related]
8. Role of epidermal growth factor receptor inhibitor-induced interferon pathway signaling in the head and neck squamous cell carcinoma therapeutic response.
Korpela SP; Hinz TK; Oweida A; Kim J; Calhoun J; Ferris R; Nemenoff RA; Karam SD; Clambey ET; Heasley LE
J Transl Med; 2021 Jan; 19(1):43. PubMed ID: 33485341
[TBL] [Abstract][Full Text] [Related]
9. Detection of TIMP3 promoter hypermethylation in salivary rinse as an independent predictor of local recurrence-free survival in head and neck cancer.
Sun W; Zaboli D; Wang H; Liu Y; Arnaoutakis D; Khan T; Khan Z; Koch WM; Califano JA
Clin Cancer Res; 2012 Feb; 18(4):1082-91. PubMed ID: 22228635
[TBL] [Abstract][Full Text] [Related]
10. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma.
Leblanc O; Vacher S; Lecerf C; Jeannot E; Klijanienko J; Berger F; Hoffmann C; Calugaru V; Badois N; Chilles A; Lesnik M; Krhili S; Bieche I; Le Tourneau C; Kamal M
Cancer Biol Med; 2020 Feb; 17(1):208-217. PubMed ID: 32296588
[No Abstract] [Full Text] [Related]
12. CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab.
Niehr F; Weichert W; Stenzinger A; Budach V; Tinhofer I
J Transl Med; 2015 Apr; 13():106. PubMed ID: 25890004
[TBL] [Abstract][Full Text] [Related]
13. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.
Lu H; Li X; Lu Y; Qiu S; Fan Z
Cancer Lett; 2016 Oct; 381(1):23-30. PubMed ID: 27450723
[TBL] [Abstract][Full Text] [Related]
14. EGFR overexpression increases radiotherapy response in HPV-positive head and neck cancer through inhibition of DNA damage repair and HPV E6 downregulation.
Alsahafi EN; Thavaraj S; Sarvestani N; Novoplansky O; Elkabets M; Ayaz B; Tavassoli M; Legends MF
Cancer Lett; 2021 Feb; 498():80-97. PubMed ID: 33137407
[TBL] [Abstract][Full Text] [Related]
15. Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy.
Pogorzelski M; Ting S; Gauler TC; Breitenbuecher F; Vossebein I; Hoffarth S; Markowetz J; Lang S; Bergmann C; Brandau S; Jawad JA; Schmid KW; Schuler M; Kasper S
Cell Death Dis; 2014 Feb; 5(2):e1091. PubMed ID: 24577089
[TBL] [Abstract][Full Text] [Related]
16. Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma.
Michmerhuizen NL; Leonard E; Matovina C; Harris M; Herbst G; Kulkarni A; Zhai J; Jiang H; Carey TE; Brenner JC
Mol Pharmacol; 2019 May; 95(5):528-536. PubMed ID: 30858165
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer.
Cohen EEW; Licitra LF; Burtness B; Fayette J; Gauler T; Clement PM; Grau JJ; Del Campo JM; Mailliez A; Haddad RI; Vermorken JB; Tahara M; Guigay J; Geoffrois L; Merlano MC; Dupuis N; Krämer N; Cong XJ; Gibson N; Solca F; Ehrnrooth E; Machiels JH
Ann Oncol; 2017 Oct; 28(10):2526-2532. PubMed ID: 28961833
[TBL] [Abstract][Full Text] [Related]
18. AKT can modulate the
Silva-Oliveira RJ; Melendez M; Martinho O; Zanon MF; de Souza Viana L; Carvalho AL; Reis RM
Oncotarget; 2017 Aug; 8(32):53288-53301. PubMed ID: 28881811
[TBL] [Abstract][Full Text] [Related]
19. Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines.
De Pauw I; Wouters A; Van den Bossche J; Deschoolmeester V; Baysal H; Pauwels P; Peeters M; Vermorken JB; Lardon F
Cancer Biother Radiopharm; 2017 Sep; 32(7):229-238. PubMed ID: 28910149
[TBL] [Abstract][Full Text] [Related]
20. Genetic and chemical targeting of epithelial-restricted with serine box reduces EGF receptor and potentiates the efficacy of afatinib.
Zhang M; Taylor CE; Piao L; Datta J; Bruno PA; Bhave S; Su T; Lang JC; Xie X; Teknos TN; Mapp AK; Pan Q
Mol Cancer Ther; 2013 Aug; 12(8):1515-25. PubMed ID: 23723125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
